Shanghai Medicilon Inc.

  In vitro  biological activity detection is a mandatory item for clinical application of biological products, with high requirements for method development, personnel operation stability, and laboratory compliance management. Medicilon's cell viability assay platform can provide compliant  in vitro  cell viability detection services that meet the application requirements. Our high-level scientific research team can assist customers in participating in new drug development and exploring drug action mechanisms, while our high-throughput screening platform can help customers conduct efficient drug screening. Empowering new drug development Wide variety Medicilon offers over  400  kinds of cell models, providing detection services and functional assay services for various signal pathways. Various Methods Cell viability assays Reporter gene assays TR-FRET FACS Radioactive assays mRNA and protein expression level detection Sample provision Customers only need t...

Comparing the human genome with the mouse genome reveals both shared general principles and important differences in how each species’ genes are regulated. For years, scientists have considered the laboratory mouse one of the best models for researching disease in humans because of the genetic similarity between the two mammals. Now, researchers at the Stanford University School of Medicine have found that the basic principles of how genes are controlled are similar in the two species, validating the mouse’s utility in clinical research. However, there are important differences in the details of gene regulation that distinguish us as a species. “At the end of the day, a lot of the genes are identical between a mouse and a human, but we would argue how they’re regulated is quite different,” said Michael Snyder, PhD, professor and chair of genetics at Stanford. “We are interested in what makes a mouse a mouse and a human a human.” The research effort, Mouse ENCODE, is meant to...

Nov. 18-21, 2014 Centre de Convencions Internacional Barcelona (CCIB) Barcelona, Spain Late Registration Deadline: Friday, Nov. 14, 2014 Symposium Co-Chairpersons Jean-Charles Soria, Institut Gustave-Roussy, Villejuif, France (EORTC) Lee J. Helman, National Cancer Institute, Bethesda, Md., USA (NCI) Jeffrey A. Engelman, Massachusetts General Hospital, Boston, Mass., USA (AACR) Symposium Website View Program Register Now and Save Hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR), the 2014 Symposium will bring together over 2,000 academics, scientists, and pharmaceutical industry representatives from across the globe to discuss innovations in drug development, target selection and the impact of new discoveries in molecular biology . During the last few years, numerous innovative agents have been discovered as a result of tremendous developments i...

Our structural biology department offers services supporting structure-based drug discovery from determination of novel targets to final structures. Our platform is one of the earliest established structural biology platform in China and has been certified by the Shanghai government. Enzymatic-Based Assay Multiple Technology Platforms Lance Assay Alphascreen Assay Z’-LYTE Assay Adapta Assay Kinase-Glo Assay ADP-Glo Assay Ligand Binding ELISA Assay HTRF Assay Diversified Targets and Applications Kinases GPCR Proteases Transcription Factors Cytokines Metabolic Enzymes Biomarker Protein Binding Protein Interacting Compound screening Cell-Based Assay Cytotoxicity Assay Apoptosis Assay Cell Migration Assay Cell Invasion Assay HTRF Cell-based Assay Immunostaining Assay Immunofluorescence Assay (96/384 wells) Reporter Gene Assay (GFP/Luc) Radioactive Ligand/receptor Binding Assay Cellular Uptake Assay Gene Knockdown Assay MicroRNA Overexp...